Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that arises in the stem cell compartment [1, 2] . Th e molecular hallmark of the disease is the BCR-ABL gene rearrangement [3, 4] , which usually occurs as the result of a reciprocal translocation between chromosomes 9 and 22 [5] . Th e molecular consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein. Th is most frequently has a molecular weight of 210 kD (p210Bcr/Abl) and has increased tyrosine kinase activity, which is essential to its transforming capability [6] . Imatinib (previously STI571), a small molecule tyrosine kinase inhibitor (TKI), was the fi rst drug that targeted BCR-ABL and it has become the standard frontline therapy for CML [7] . Th e majority of patients will do well on standard therapy. However, some patients will fail on imatinib and require alternative therapies. Currently, the main tool to identify high-risk patients is close monitoring of their in vivo response to therapy [8] . Realtime quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemia cell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with progression-free survival [9] . If they do not achieve a complete hematologic response with 3 months of imatinib, if they are predominantly PH positive at 6 months or still have >35% PH positive metaphases at 12 months, or the loss of a previous hematologic or cytogenetic response, or had a 1 log increase in BCR-ABL transcripts in patients who had achieved a complete cytogenetic response, is defi ned as failure to imatinib therapy [10] . Identifi cation of those patients who are likely to fail is desirable to allow for more intensive therapy up front [8] .
Material and methods
At the Clinical Hematology and BMT Unit Tîrgu Mureș, between 2008-2011 we performed the molecular monitoring of bcr-abl transcript levels with RQ-PCR in 16 patients diagnosed with CML. We collected a complete set of baseline data: a clinical examination with documentation of spleen size, complete blood count (CBC) with white blood cell diff erential, and bone marrow biopsy with metaphase karyotyping, RQ-PCR for BCR-ABL rearrangement. For the patients in advanced phase of the disease, fl owcytoCorrespondence to: Aliz-Beáta Tunyogi E-mail: tunyogializ@yahoo.co.uk metry was performed from bone marrow to determine the percent and the phenotype of the blast cells.
Due to the small size of the sample of patients, statistic analysis seemed to be inappropriate.
Results
Th e median age at diagnosis was 44 years. Th e majority of the patients were in fi rst chronic phase at diagnosis (10 patients, 62%), 3 patients (19%) in accelerated phase and 3 patients (19%) in blast crisis. Th e Sokal score was calculated and 15 patients were identifi ed as high risk patients, while one patient presented intermediary prognostic score.
Th e 1 st patient is a 48 year old female, diagnosed with CML in 1996, fi rst treated with hydroxiureea and then with imatinib 400 mg/day. In 2006, under the imatinib treatment, the disease progressed to accelerated phase (bcrabl transcript levels 25.8%).
Th e patient's dose was escalated to imatinib 600 mg/day, but she presented blastic transformation (80% blasts in peripheral blood). In March 2008 we performed the allogeneic stem cell transplantation from an HLA identical sibling. Immunosuppression was performed with Cyclosporine + Methotrexate. She presents mild chronic GVHD under low dose immunosuppression (Medrol 4 mg). She is in complete molecular remission 4 years after the transplantation.
Th e 2 nd patient is a 41 year old male, diagnosed in 2007. Under imatinib treatment 400 mg/day he presented blastic transformation of the disease (fl owcytometry performed).
In September 2008 we performed the allogeneic stem cell transplantation from an HLA identical sibling donor. Immunosuppression was performed with Cyclosporine + Methotrexate. Th e patient did not present any signs of GVHD. Short time after the transplantation an early relapse occurred. We stopped the immunosuppression and initiated Imatinib 600 mg/day and donor lymphocyte infusion (DLI), with no response. In January 2009 the fl owcytometry revealed 30% of blasts in peripheral blood and bcr-abl levels were 142%. We initiated treatment with high dose chemotherapy and dasatinib 2 × 70 mg/day. In May 2009 the peripheral blast count (80%) and the bcrabl transcript levels were increasing (188%).
We switched the dasatinib to nilotinib 2 × 400 mg/day. A year after transplantation and HD chemotherapy the patient presented left lobar pneumonia, septicemia and died due to multiorgan failure.
Th e 3 rd case was in accelerated phase of the disease at presentation, received imatinib 400 mg/day, but the levels of bcr-abl transcripts increased and the patient's dose was escalated to Imatinib 600 mg/day.
Th e 4 th case was under treatment with hydroxiureea presenting blastic transformation, bcr-abl transcript levels were 167.3%. Th e patient received induction chemotherapy and imatinib 600 mg/day. Th e patient went to the second chronic phase (bcr-abl transcript levels 24.9%). After four months under imatinib the patient presented 90% of blasts and increasing transcript levels (199%). Under high dose chemotherapy + dasatinib 2 × 70 mg/day the transcript levels decreased (75%).
In the 5 th case, with blast crisis on presentation, bcr-abl transcript levels were 34%. We initiated induction chemotherapy and imatinib 600 mg/day. Th e transcript levels increased (42%) and we switched to the second generation of TKIs -dasatinib 2 × 70 mg/day and then nilotinib 2 × 400 mg/day, with slightly decreasing transcript levels (28%), but no hematological response.
In the 6 th case we witnessed a loss of complete molecular response after 5 years of imatinib treatment 400 mg/day. Th e switch to the second generation of TKI the mutational analysis and cytogenetic reevaluation are indicated.
We have 10 patients on imatinib 400 mg/day, 3 of them in accelerated phase and 7 in chronic phase at diagnosis, who achieved major molecular response, and four of them completed molecular response with no detectable transcript levels. Th e median follow-up time was 5 years and 6 months.
Discussion
With the introduction of TKIs in CML therapy, the outstanding therapeutic results have shifted the attention to molecular studies. Patients with Philadelphia chromosome (Ph)-positive CML who are in complete cytogenetic response (CCyR) on tyrosine kinase inhibitors (TKIs), are frequently monitored for response by RQ-PCR for minimal molecular disease, to identify which patients in CCyR would have a high likelihood of relapse, and who might therefore benefi t from escalating the imatinib dose or changing therapy to the more potent second generation TKIs or allogeneic stem cell transplantation. In the fi rst two patients with identical sibling donors the increasing transcript levels under imatinib helped us to decide for allogeneic stem cell transplantation. In the second case the increasing transcript levels determined us to stop the immunosuppression and administer donor lymphocyte infusion before the hematological changes appeared and guided our decision of switch between second generations of TKI. In three cases the increasing transcript levels and the absence of hematological response determined us to initiate treatment with second generation TKI.
In our lot 68.5% of patients achieved major molecular response. Among these patients only two were in accelerated phase of the disease, the others presented in the fi rst chronic phase. Responses are durable in most patients treated in early chronic phase, particularly among those who achieve major molecular responses [6] . Th e median time for follow-up was 5 years and 6 months and we witnessed the loss of complete molecular response in only one patient. Patients who lose MMR or never achieve MMR, and have more than 1 log increase of RQ-PCR, should be monitored more closely, and may be evaluated for mutations of BCR-ABL kinase domain and considered for investigational therapeutic interventions [11] .
Conclusions
• Th e RQ-PCR is a proven method for the monitoring of Ph-positive CML patients who are in complete cytogenetic response (CCyR) on tyrosine kinase inhibitors, for the evaluation of therapeutic response.
• Increasing transcriptional levels of BCR-ABL is an early indicator of the loss of therapeutic response and could provide clinical benefi ts by triggering early therapeutic interventions.
• RQ-PCR provides an accurate measure of the total leukemic cell mass. In those patients who achieved major molecular response on TKIs the response is durable and is associated in our study with progression-free survival.
• Patients who lose MMR or never achieve MMR, and have more than 1 log increase of RQ-PCR, should be monitored more closely. 
